Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011

详细信息    查看全文

• 作者：Y. Chavarri-Guerra^a ; ^b ; J. St. Louis^a ; ^c ; A. Bukowski^a ; ^c ; E. Soto-Perez-de-Celis^a ; ^d ; P.E.R. Liedke^a ; ^e ; ^f ; H. Symecko^g ; B. Moy^h ; M. Higginsⁱ ; D.M. Finkelstein^g ; P.E. Goss^a ; ^c ; ^h ; ^{pgoss@mgh.harvard.edu}
• 关键词：Breast neoplasm ; HER2 ; Health care disparities ; Molecular targeted therapy
• 刊名：The Breast
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：31
• 期：Complete
• 页码：197-201
• 全文大小：665 K
• 卷排序：31

文摘

HER2+ breast cancer patients in LMICs may not receive standard adjuvant therapy. Responders reported instances when they recommended trastuzumab but the patient did not receive it. Our survey cites cost and lack of high quality HER2 testing as barriers to adjuvant therapy.